Pamidronate “zebra lines”: A treatment timeline [PDF]
Radiology Case Reports, 2017 Osteogenesis imperfecta is a hereditary bone dysplasia characterized by bone fragility, deformity, and short stature. Treatment focuses on preventing bone fractures and symptom relief.
Avgi Loizidou, BSc, MBChB +2 more
doaj +3 more sources
Pamidronate Disodium for Palliative Therapy of Feline Bone-Invasive Tumors [PDF]
Veterinary Medicine International, 2014 This study sought to quantify in vitro antiproliferative effects of pamidronate in feline cancer cells and assess feasibility of use of pamidronate in cats by assessing short-term toxicity and dosing schedule in cats with bone-invasive cancer.
Jackie M. Wypij, David A. Heller
doaj +2 more sources
Pamidronate is ineffective for inflammatory-like low back pain associated with Modic type 1 changes: A double-blind, randomised controlled trialKey points [PDF]
Osteoarthritis and Cartilage OpenObjective: Modic type 1 (MC-1) vertebral endplate changes are associated with chronic low back pain (LBP) and often reflect an inflammatory process. Pamidronate has demonstrated analgesic effects in conditions involving bone marrow oedema.
Martin Soubrier +9 more
doaj +2 more sources
Evaluation of the efficacy and tolerance of pamidronate in complex regional pain syndrom type 1 [PDF]
Scientific ReportsThis study aimed to determine whether the delay between symptom onset and treatment initiation, the dose of pamidronate, and bone mineral density (BMD) influence the response to pamidronate treatment in complex regional pain syndrome type 1 (CRPS 1).
Marie Doussiere +7 more
doaj +2 more sources
Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC [PDF]
PeerJ, 2020 Background Bisphosphonate therapy has become a popular treatment for osteoporosis, Paget’s disease, multiple myeloma, osteogenesis imperfecta, myocardial infarction, and cancer despite its serious side effects.
Sang Shin Lee +3 more
doaj +2 more sources
Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials. [PDF]
PLoS ONE, 2014 INTRODUCTION: The overall effect of pamidronate on bone mass density (BMD) in the early renal transplant period varies considerably among studies. The effects of pamidronate on graft function have not been determined.
Zijie Wang +10 more
doaj +1 more source
In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. [PDF]
PLoS ONE, 2012 It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease. This lack of clarity primarily stems from the
Yan Wang, Bo Lin
doaj +1 more source
Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Purpose Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single ...
Yunha Choi +5 more
doaj +1 more source
The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice. [PDF]
PLoS ONE, 2015 A novel avian influenza virus H7N9 infection occurred among human populations since 2013. Although the lack of sustained human-to-human transmission limited the epidemics caused by H7N9, the late presentation of most patients and the emergence of ...
Jian Zheng +14 more
doaj +1 more source
Pediatric Rheumatology Online Journal, 2009 Background Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory, non-infectious osteopathy that affects predominantly patients ≤ 18 years of age. There is no uniformly effective treatment.
Reslan Walid +5 more
doaj +1 more source